Grant: Master's Award: Canada Graduate Scholarships
University of British Columbia
$17,500.00
Exploration of Novel Pharmacological Treatments for Iatrogenic Gambling Disorder Induced by Parkinson’s Disease Treatment
EF 2017-18
Résumé
Parkinson's Disease (PD) affects 1-2 individuals per 1000 of the population at any time and is characterized by the degeneration of dopamine (DA) neurons in motor areas of the brain, thereby producing debilitating motor symptoms like resting tremors. Due to the loss of DA neurons and therefore DA, dopamine replacement therapy is used to treat PD. However, the most commonly used treatment, L-DOPA, only has a short window of efficacy and can produce debilitating side-effects. An alternative treatment utilizing DA agonists is available (e.g. ropinirole); although it is effective at treating PD symptoms, it can produce impulse control disorders (ICDs) like gambling disorder (GD), compulsive buying, and binge-eating disorder. Moreover, this devastating side-effect has also been observed in PD patients receiving L-DOPA. It's estimated that 1 in 7 patients with PD hasan ICD; therefore, underscoring the need for an effective treatment. I aim to test different pharmacological treatments for GD on rodent models of GD and PD. I will use the DA agonist, ropinirole, to produce GD like behaviour in rats. Subsequently, I will test pharmacological treatments on these animals and measures their behaviour via the rat betting task. If the treatment is effective, it should prevent or reduce GD like behaviour in rats that is caused by ropinirole. This will be done on both normal animals and rodent models of PD, to show if the treatment is effective with and without the complexity of PD. Additionally, by using a rodent model of PD, it will be clear if the treatment interferes with the ability of ropinirole to reduce PD symptoms. If an effective treatment is found, it would not only be valuable for those with PD struggling with GD, but for all individuals struggling with ICDs.
Programme
Master's Award: Canada Graduate Scholarships
Bénéficiaire
Emplacement
British Columbia, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database
Tel que publié
Id
386424
Name
Russell Brittney
Region
British Columbia
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Exploration of Novel Pharmacological Treatments for Iatrogenic Gambling Disorder Induced by Parkinson’s Disease Treatment
Programtype2
Studentship Programs
Orgnameinp2
University of British Columbia
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Dopamine Agonist; Gambling Disorder; Impulse Control Disorders; Impuslivity; Parkinson'S Disease; Risky Choice; Rodent Model; Ropinirole; Treatment
Abstract
Parkinson's Disease (PD) affects 1-2 individuals per 1000 of the population at any time and is characterized by the degeneration of dopamine (DA) neurons in motor areas of the brain, thereby producing debilitating motor symptoms like resting tremors. Due to the loss of DA neurons and therefore DA, dopamine replacement therapy is used to treat PD. However, the most commonly used treatment, L-DOPA, only has a short window of efficacy and can produce debilitating side-effects. An alternative treatment utilizing DA agonists is available (e.g. ropinirole); although it is effective at treating PD symptoms, it can produce impulse control disorders (ICDs) like gambling disorder (GD), compulsive buying, and binge-eating disorder. Moreover, this devastating side-effect has also been observed in PD patients receiving L-DOPA. It's estimated that 1 in 7 patients with PD hasan ICD; therefore, underscoring the need for an effective treatment. I aim to test different pharmacological treatments for GD on rodent models of GD and PD. I will use the DA agonist, ropinirole, to produce GD like behaviour in rats. Subsequently, I will test pharmacological treatments on these animals and measures their behaviour via the rat betting task. If the treatment is effective, it should prevent or reduce GD like behaviour in rats that is caused by ropinirole. This will be done on both normal animals and rodent models of PD, to show if the treatment is effective with and without the complexity of PD. Additionally, by using a rodent model of PD, it will be clear if the treatment interferes with the ability of ropinirole to reduce PD symptoms. If an effective treatment is found, it would not only be valuable for those with PD struggling with GD, but for all individuals struggling with ICDs.
Competitiondate
201712
Approvedterm2
1 yr 0 mth
Pinamesdelim
Russell, Brittney
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~